Ann Arbor, MINCT05901519Now EnrollingIRB Ready

Hepatocellular Carcinoma Clinical Trial in Ann Arbor, MI

Access cutting-edge hepatocellular carcinoma treatment through this phase 2 clinical trial at a research site in Ann Arbor. Study-provided care at no cost to qualified participants.

Sponsored by University of Michigan Rogel Cancer Center

Quick Self-Assessment

See if you qualify for this Ann Arbor location

Preparing your pre-screening questions…

Expert Care in Ann Arbor

Access hepatocellular carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hepatocellular carcinoma treatment provided free

Apply for This Ann Arbor Location

Check if you qualify for this hepatocellular carcinoma clinical trial in Ann Arbor, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Ann Arbor

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Ann Arbor site if eligible
  4. 4Begin participation

About This Hepatocellular Carcinoma Study in Ann Arbor

Patients on this study will self administer Prednisone for three days before starting Radiation Therapy (RT) and continue to take 60 mg/day during the first three fractions of RT.

Sponsor: University of Michigan Rogel Cancer Center

Who Can Participate

Inclusion Criteria

Patients with hepatocellular carcinoma are eligible for this trial. Hepatocellular carcinoma is defined as having at least one of the following:
Biopsy proven hepatocellular carcinoma (HCC); or
A discrete hepatic tumor(s) as defined by the AASLD criteria (80) - for cirrhotic patients, \>1cm with arterial hypervascularity and venous or delayed phase washout on contrast enhanced CT or MRI.
Patients must have recovered from the acute effects of prior liver-directed therapy (e.g., RT, RFA, or TACE), and a minimum of 4 weeks must have passed since the last procedure and protocol therapy.
Patients must have a performance status of ≤2.
Patients must be 18 years of age or older.
Patients with at least one of the following:
ALBI score equal to (-1.81) or higher (worse). This value was calculated as the equivalent ALBI score for CP score equal 7 in Cousins et al study's cohort(59).
Lesion(s) with a cumulative treatment diameter of ≥ 4cm.
CP score equal to 7 or higher (worse).
Patients must understand and be willing to sign an informed consent form approved for this purpose by the Institutional Review Board (IRB) of the University of Michigan Medical Center indicating that they are aware of the investigational aspects of the treatment and the potential risks.

Exclusion Criteria

Any serious disease, comorbidity or intercurrent illness which precludes delivery of radiation therapy, as determined by the treating investigator.
Any contraindication to the administration of steroids, including
Documented hypersensitivity to prednisone or any component of the formulation.
Systemic fungal infection.
Patients with uncontrolled infections or with chronic infections requiring antibiotics. Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
Uncontrolled hyperglycemia.
Patients with insulin -dependent diabetes.
Patients with decompensated liver disease, defined as: clinical ascites requiring paracentesis, hepatic encephalopathy, hepatorenal syndrome or variceal hemorrhage.
Active gastrointestinal bleeding within 30 days of enrollment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Ann Arbor?

Yes, this clinical trial (NCT05901519) has an active research site in Ann Arbor, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hepatocellular Carcinoma Treatment Options in Ann Arbor, MI

If you're searching for hepatocellular carcinoma treatment options in Ann Arbor, MI, this clinical trial (NCT05901519) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Ann Arbor research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced hepatocellular carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hepatocellular carcinoma clinical trials near you to find additional studies recruiting in your area.

More Liver Cancer Trials in Ann Arbor, MI

See all liver cancer clinical trials recruiting in Ann Arbor — not just this study.

Browse Liver Cancer Trials in Ann Arbor →

Browse More Trials by Condition

Liver Cancer TrialsAll Conditions →

Ready to Join in Ann Arbor?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Ann Arbor, MI